Respix (ambroxol hydrochloride) spray oral solution 10 mg/0.2 ml. 13 ml. vial

$32.00

Manufacturer: India

Treatment of acute and chronic respiratory diseases accompanied by violation of bronchial secretion and evacuation of secretions ( including acute and chronic bronchitis, chronic obstructive pulmonary diseases, pneumonia, bronchiectatic disease, bronchial asthma, cystic fibrosis, laryngitis, tracheitis). Use in preparation for bronchoscopy and after the study.

Categories: ,

Description

Respix (ambroxol hydrochloride) spray oral solution 10 mg/0.2 ml. 13 ml. vial

Composition 

active substance: ambroxol;

1 ml of solution contains ambroxol hydrochloride 50 mg;

1 stream of solution (0.2 ml of solution) contains ambroxol hydrochloride 10 mg;

excipients: trometamol, macrogol hydroxystearate, glycerin, acesulfame potassium, xylitol, sodium benzoate (E 211), levomenthol, ammonium glycyrrhizate, ethanol 96%, sodium hydroxide, purified water.

Medicinal form

Oral solution.

Main physicochemical properties: colorless or yellowish cloudy solution. With a faint smell of menthol.

Pharmacotherapeutic group

Mucolytics.
ATX code R05C B06.

Pharmacological properties

Ambroxol, a substituted benzylamine, is a metabolite of bromhexine.

It differs from bromhexine in the absence of a methyl group and an additional hydroxyl group in the 4 (trans)-position of the cyclohexyl ring. Although the exact mechanism of action is not fully established, various studies have shown secretolytic and secretomotor effects.

After oral administration, the effect appears after an average of 30 minutes and lasts for 6–12 hours, depending on the dose used.

In preclinical studies, ambroxol increased the amount of serous bronchial secretion. Ambroxol has been found to increase mucociliary transport by stimulating the motility of bronchial epithelium cilia and reducing mucus viscosity.

Ambroxol causes the activation of the surfactant system through a direct effect on type II pulmocytes of alveoli and secretory cells of bronchioles (the terminal section of the respiratory tract).

Ambroxol stimulates the formation and release of surface active substances in the alveolar and bronchial regions of the lungs of fetuses and adult patients.

The local anesthetic effect of ambroxol hydrochloride was observed in the rabbit eye model, which can be explained by the blocking properties of sodium channels. In vitro studies have shown that ambroxol hydrochloride blocks neuronal sodium channels; binding was reversible and concentration-dependent.

According to the results of a clinical study, when using Respix spray, a decrease in the intensity of pain in the throat was found in patients with uncomplicated respiratory diseases.

Pharmacological properties Respix 

This drug belongs to the group of a set of drugs used in the treatment of diseases of the lower respiratory system, which are accompanied by a dry cough with poor sputum separation.

The main active ingredient is ambroxol. It is produced from the plant Adhotoda vazika as one of the forms of bromhexine, being its active metabolite.
Unlike bromhexine, it does not have a methyl group, as well as an additional hydroxyl group. There is no information about the exact mechanism of its action, but it is known that ambroxol produces an active secretolytic, expectorant and secretomotor effect.
Shows activity after half an hour after ingestion, exerting its effect for 6 to 12 hours in a row. The drug activates bronchial secretion, while at the same time improving the process of removing the drug from the respiratory tract.
Promotes a decrease in the viscosity of secreted secretions in patients, regardless of the patient’s age.

Indications

This drug Respix spray can be used in the complex treatment of acute and chronic bronchopulmonary diseases, which are accompanied by dry cough, impaired mucus formation and excretion.
Before starting treatment, you should consult your doctor.

Contraindications

The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
Should not be used concomitantly with drugs that block the cough reflex due to the likelihood of excessive accumulation of bronchial secretions in the lungs.
It is not used in pediatrics until the age of 12.

Application during pregnancy and lactation

This drug is contraindicated for pregnant women and women during lactation.

Method of administration and dosage

The drug Respix spray is administered orally, in the form of injections into the oral cavity 3 times a day, that is, 30 mg 3 times a day.

After the drug enters the oral cavity, it must be swallowed. Preferably taken with or immediately after meals.
High secretion of liquid mucus requires a large amount of fluid consumed.
The duration of the course of treatment is no more than 5 days.

The patient should consult a doctor if the symptoms of the disease did not disappear during the use of the drug or if adverse reactions are observed that are not indicated in the instructions for medical use of the drug.

Overdose

Overdose in significant doses has not been observed to date.
In rare cases, nausea and diarrhea, dyspeptic symptoms, disorders of the gastrointestinal tract were noted.
In case of overdose, you should rinse the stomach, take sorbents.

Side effects

Usually, this drug is well tolerated without causing complications.
In theory, the use of this drug can occasionally cause allergic side reactions, in particular, such as:

  • allergic urticaria, itching, rash, hyperemia;
  • nausea, vomiting, abdominal pain, heartburn;
  • upset gastrointestinal tract;
  • dysgeusia, dry mouth, throat.

If side effects occur, the drug should be discontinued, symptomatic therapy should be undertaken, consult a doctor and the treatment regimen should be adjusted.